Stock analysts at Guggenheim initiated coverage on shares of C4 Therapeutics (NASDAQ:CCCC – Get Free Report) in a report issued on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $6.00 price target on the stock. Guggenheim‘s target price suggests a potential upside of 93.55% from the stock’s previous close.
A number of other analysts have also issued reports on the stock. JPMorgan Chase & Co. started coverage on shares of C4 Therapeutics in a research note on Friday, October 9th. They set an “overweight” rating and a $10.00 price target on the stock. Evercore downgraded shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Lake Street Capital initiated coverage on shares of C4 Therapeutics in a report on Wednesday, October 28th. They set a “buy” rating and a $11.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, C4 Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $8.50.
View Our Latest Analysis on C4 Therapeutics
C4 Therapeutics Stock Performance
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%. The company had revenue of $8.47 million for the quarter, compared to analysts’ expectations of $8.52 million. On average, sell-side analysts expect that C4 Therapeutics will post -0.81 earnings per share for the current fiscal year.
Hedge Funds Weigh In On C4 Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its position in shares of C4 Therapeutics by 27.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,447 shares of the company’s stock worth $70,000 after buying an additional 4,850 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in C4 Therapeutics in the third quarter worth approximately $34,000. SummitTX Capital L.P. purchased a new position in C4 Therapeutics in the first quarter worth approximately $28,000. CTC Alternative Strategies Ltd. purchased a new position in C4 Therapeutics in the first quarter worth approximately $28,000. Finally, Russell Investments Group Ltd. grew its holdings in C4 Therapeutics by 170.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,924 shares of the company’s stock worth $73,000 after acquiring an additional 13,819 shares in the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.
About C4 Therapeutics
C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.
C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
